13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BO29554 B.FAST

    Acronym: 

    BO29554 B.FAST

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II, Phase III Tumour Stream Non-small lung cancer
    Age Range 18 years and older Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II, Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Non-small lung cancer
    Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase II/III multicenter study evaluating the efficacy and safety of multiple targeted therapies as treatments for patietns with advanced or metastatic non-small lung cancer harboring actionable somatic mutations detected in blood (B-Fast: Blood-First Assay Screening Trial)

    Lay Summary

    Sponsor / Cooperative group

    Roche

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting